FOURPOINTS Investment Managers S.A.S. reduced its position in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 12.5% during the first quarter, Holdings Channel reports. The institutional investor owned 30,818 shares of the medical research company’s stock after selling 4,400 shares during the period. Thermo Fisher Scientific accounts for about 4.9% of FOURPOINTS Investment Managers S.A.S.’s investment portfolio, making the stock its 2nd largest position. FOURPOINTS Investment Managers S.A.S.’s holdings in Thermo Fisher Scientific were worth $4,734,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Independent Portfolio Consultants Inc. raised its stake in shares of Thermo Fisher Scientific by 0.3% in the first quarter. Independent Portfolio Consultants Inc. now owns 730 shares of the medical research company’s stock worth $112,000 after buying an additional 2 shares during the last quarter. Sharkey Howes & Javer raised its stake in shares of Thermo Fisher Scientific by 1.0% in the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock worth $113,000 after buying an additional 7 shares during the last quarter. Penserra Capital Management LLC raised its stake in shares of Thermo Fisher Scientific by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,150 shares of the medical research company’s stock worth $176,000 after buying an additional 100 shares during the last quarter. South Texas Money Management Ltd. purchased a new stake in shares of Thermo Fisher Scientific during the first quarter worth approximately $202,000. Finally, Fairfax Financial Holdings Ltd Can purchased a new stake in shares of Thermo Fisher Scientific during the first quarter worth approximately $206,000. 87.15% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Inc (NYSE:TMO) traded down 0.632% during trading on Thursday, hitting $172.165. The stock had a trading volume of 356,199 shares. Thermo Fisher Scientific Inc has a 1-year low of $139.07 and a 1-year high of $182.87. The stock’s 50-day moving average price is $176.96 and its 200-day moving average price is $165.20. The company has a market capitalization of $67.16 billion, a P/E ratio of 29.994 and a beta of 1.06.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, topping analysts’ consensus estimates of $2.27 by $0.03. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The business had revenue of $5 billion during the quarter, compared to the consensus estimate of $4.92 billion. During the same quarter in the previous year, the firm posted $2.03 EPS. The firm’s revenue was up 10.2% on a year-over-year basis. Analysts expect that Thermo Fisher Scientific Inc will post $9.24 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be given a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.35%. The ex-dividend date is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.45%.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/10/fourpoints-investment-managers-s-a-s-has-4-73-million-position-in-thermo-fisher-scientific-inc-nysetmo.html.

TMO has been the subject of a number of research analyst reports. Morgan Stanley boosted their target price on Thermo Fisher Scientific from $186.00 to $192.00 and gave the company an “overweight” rating in a research report on Friday, April 28th. Deutsche Bank AG boosted their target price on Thermo Fisher Scientific from $163.00 to $188.00 and gave the company a “buy” rating in a research report on Friday, April 28th. Barclays PLC reaffirmed an “overweight” rating and issued a $190.00 target price (up from $175.00) on shares of Thermo Fisher Scientific in a research report on Tuesday, May 9th. Leerink Swann set a $187.00 target price on Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Thursday, April 27th. Finally, Cowen and Company reaffirmed an “outperform” rating and issued a $185.00 target price (up from $175.00) on shares of Thermo Fisher Scientific in a research report on Saturday, April 29th. One research analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. Thermo Fisher Scientific has a consensus rating of “Buy” and an average target price of $188.56.

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 2,500 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $176.26, for a total value of $440,650.00. Following the completion of the sale, the chief financial officer now owns 37,790 shares of the company’s stock, valued at approximately $6,660,865.40. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Marc N. Casper sold 20,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $172.79, for a total transaction of $3,455,800.00. Following the completion of the sale, the chief executive officer now directly owns 269,279 shares of the company’s stock, valued at approximately $46,528,718.41. The disclosure for this sale can be found here. In the last ninety days, insiders sold 27,188 shares of company stock valued at $4,702,223. 0.49% of the stock is currently owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.